The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

International Journal of Obesity

Volumn 23, Issue 10, 1999, Pages 1016-1024

  Hansen, D L ^a   Toubro, S ^a   Stock, M J ^b   Macdonald, I A ^c   Astrup, A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Appetite; Human; Obesity; Sibutramine; Thermogenesis

Indexed keywords

PLACEBO; SIBUTRAMINE;

ADULT; APPETITE; ARTICLE; BREATHING; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SATIETY; THERMOGENESIS; WEIGHT REDUCTION;

EID: 0032856399     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801059     Document Type: Article

References (33)

1. 1 World Health Organization. Obesity, preventing and managing the global epidemic. Geneva. WHO 1998; 17.
2. 2 Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. Br Med J 1997: 314: 29-34.
3. 3 Wadden T, Sternberg J, Letizia K, Stunkard A, Foster G. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989; 13(2): 39-46.
4. 4 Grundlah C, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 1997; 283: 581-591.
5. 5 Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263-270.
6. 6 Hanotin C, Thomas F, Jones SP, Leutenegger H, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes 1998; 22: 32-38.
7. 7 Weintraub M, Byrne L, Golik A, Rubio A. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991; 50: 330-337.
8. 8 Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998; 6: 115-121.
9. 9 Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997; 21(Suppl 1): S25-S29.
10. 10 Rolls BJ, Thorwart ML, Shide DJ, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6: 1-11.
11. 11 Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup AV. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-1186.
12. 12 Hill AJ, Magson LD, Blundell JE. Hunger and palatability: Tracking ratings of subjective experience before, during and after the consumption of preferred and less preferred food. Appetite 1984; 5: 361-371.
13. 13 Astrup A, Thorbek G, Lind J, Isaksson B. Prediction of 24-h energy expenditure and its components from physical characteristics and body composition in normal-weight humans. Am J Clin Nutr 1990; 52: 777-783.
14. 14 Livesey G, Elia M. Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fules. Am J Clin Nutr 1988; 47: 608-628.
15. 15 Klausen B, Toubro S Astrup A. Age and sex effects on energy expenditure. Am J Clin Nutr 1997; 65: 895-907.
16. 16 Ravussin R, Bogardus C. Relationship of genetics, age and physical fitness to daily energy expenditure and fuel utilization. Am J Clin Nutr 1989; 49: 968-975.
17. 17 Murgatroyd PR, Davies HL, Prentice AM. Intra-individual variability and measurement noise in estimates of energy expenditure by whole body indirect calorimetry. Br J Nutr 1987; 58: 347-356.
18. 18 DeBoer JO, Van Es AJH, Vogt JE. Reproducibility of 24-h energy expenditure measurements using a human whole body indirect calorimeter. Br J Nutr 1987; 57: 201-209.
19. 19 Toubro S, Christensen NJ, Astrup A. Reproducibility of 24-h energy expenditure, substrate utilization and spontaneous physical activity in obesity measured in a respiration chamber. Int J Obes 1995; 19: 544-549.
20. 20 Rumpler W, Seale J, Conway J, Moe P. Repeatability of 24-h energy expenditure measurements in human by indirect calorimetry. Am J Clin Nutr 1990; 51: 147-152.
21. 21 Astrup A, Toubro S, Buemann B, Christensen NJ, Thorbek G, Victor AJ, Quaade F. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 1992; 41: 686-688.
22. 22 Seagle HM, Bessessen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998; 6: 115-121.
23. 23 Raben A, Tagliabue A, Astrup A. The reproducibility of subjective appetite scores. Br J Nutr 1995; 73: 517-530.
24. 24 Goldstein D, Potvin H. Long-term weight loss: the effect of pharmacological agents. Am J Clin Nutr 1994; 60: 647-657.
25. 25 Astrup A, Buemann B, Christensen NJ, Madsen J, Gluud C, Bennett P, Svenstrup B. The contribution of body composition, substrates, and hormones to the variability in energy expenditure and sybstrate utilization in premenopausal women. J Clin Endocrinol Metab 1992; 74: 279-286.
26. 26 Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr 1999; 69: 1117-1122.
27. 27 Welle S, Korbes G, Statt M, Barnard R, Amatruda J Energy expenditure under free-living conditions in normal-weight and overweight women. Am J Clin Nutr 1992; 55: 14-21.
28. 28 Amatruda J, Statt M, Welle S. Total and resting energy expenditure in obese women reduced to ideal body weight. J Clin Invest 1993; 92: 1236-1242.
29. 29 Hubert H, Feinleib M, McNamara P, Castelli W. Obesity as an independent risk factor for cardiovascular diseases: a 26 year follow-up of participants in the Framingham Heart Study. Circulaton 1983; 67: 968-977.
30. 30 Astrup A, Macdonald IA. In: Bray GA, Bouchard C, James WPT (eds), Sympathoadrenal system and metabolism. Handbook of Obesity, New York: Marcel Dekker Inc; 1997; 23: pp 491-511.
31. 31 Hirsch J, Rosenbaum M, Leibel LR. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628.
32. 32 Prentice AM, Goldbert G, Jebb SA, Black A, Murgatroyd PR. Physiological responses to slimming. Proc Nutr Soc 1991; 50: 441-458.
33. 33 Ravussin E. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 1988; 318: 467-473.